Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Academic Article uri icon

Overview

abstract

  • Survivors of pediatric Hodgkin's lymphoma are at risk for radiation therapy-induced second malignant neoplasms (SMNs). We identified two variants at chromosome 6q21 associated with SMNs in survivors of Hodgkin's lymphoma treated with radiation therapy as children but not as adults. The variants comprise a risk locus associated with decreased basal expression of PRDM1 (encoding PR domain containing 1, with ZNF domain) and impaired induction of the PRDM1 protein after radiation exposure. These data suggest a new gene-exposure interaction that may implicate PRDM1 in the etiology of radiation therapy-induced SMNs.

publication date

  • July 24, 2011

Research

keywords

  • Chromosomes, Human, Pair 6
  • Gene Expression Regulation, Neoplastic
  • Hodgkin Disease
  • Mutation
  • Neoplasms, Second Primary
  • Radiotherapy
  • Repressor Proteins

Identity

PubMed Central ID

  • PMC3229923

Scopus Document Identifier

  • 79961155567

Digital Object Identifier (DOI)

  • 10.1038/nm.2407

PubMed ID

  • 21785431

Additional Document Info

volume

  • 17

issue

  • 8